Previous work at CU Cancer Center shows these drugs are especially
useful against lung cancers that over-express both EGFR and HER2, implying that in addition to targeting HER2 - positive lung cancers with drugs approved to treat HER2 - positive breast cancers, there may be a role for HER2 inhibitors in HER2 cancers, perhaps both breast and lung.